These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 269705)

  • 21. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of oral BCG in the treatment or metastatic malignant melanoma.
    Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA
    Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
    Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
    Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1979; 49(2):140-5. PubMed ID: 475550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer.
    Wile AG; Sparks FC; Morton DL
    Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intrafocal BCG therapy of metastasizing malignant melanoma].
    Kunze J; Lesch R; Plagwitz R; Hagedorn M
    Hautarzt; 1978 Nov; 29(11):597-600. PubMed ID: 721465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined BCG and irradiation treatment of skin metastases originating from malignant melanoma.
    Plesnicar S; Rudolf Z
    Cancer; 1982 Sep; 50(6):1100-6. PubMed ID: 7104950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Side effects of BCG immune therapy in 511 patients with malignant melanoma].
    Schult C
    Hautarzt; 1984 Feb; 35(2):78-83. PubMed ID: 6706581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL; Eilber FR; Holmes EC; Ramming KP
    Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of disseminated malignant melanoma with high-dose oral BCG.
    Varella AD; Bandiera DC; de Amorim AR; Calvis LA; Santos IO; Escaleira N; Gentil F
    Cancer; 1981 Sep; 48(6):1353-62. PubMed ID: 7023654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intralesional BCG in the treatment of metastatic malignant melanoma.
    Mastrangelo MJ; Sulit HL; Prehn LM; Bornstein RS; Yarbro JW; Prehn RT
    Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
    Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant BCG immunotherapy for malignant melanoma.
    Paterson AH; Willans DJ; Jerry LM; Hanson J; McPherson TA
    Can Med Assoc J; 1984 Oct; 131(7):744-8. PubMed ID: 6383591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epilesional scarification. Preliminary report of a new approach to local immunotherapy with BCG.
    Richman SP; Mavligit GM; Wolk R; Gutterman JU; Hersh EM
    JAMA; 1975 Dec; 234(12):1233-5. PubMed ID: 1242748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunotherapy of malignant melanoma].
    Adler A
    Harefuah; 1986 Jul; 111(1-2):11-7. PubMed ID: 3781371
    [No Abstract]   [Full Text] [Related]  

  • 38. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
    Berd D; Mastrangelo MJ
    Cancer Invest; 1988; 6(3):337-49. PubMed ID: 3167614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
    McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
    Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.